Learn what the new policy means for your agency: compliance, oversight, and actionable strategies for public sector leaders.
On July 28, 2026, the U.S. Department of Health and Human Services released the United States Government Policy for Stopping High-Risk Life Sciences Research, banning federally supported dangerous gain-of-function studies.1 This executive action shifts the compliance burden from federal grant-makers to institutional research administrators.
For public administrators managing federal grants, the policy redefines oversight responsibilities without additional funding or infrastructure, forcing a recalibration of institutional compliance workflows. Research administrators now assume frontline responsibility for interpreting and enforcing biosecurity mandates with existing tools.
What does the new federal policy actually ban, and what does it allow?
The policy defines dangerous gain-of-function (DGoF) research as scientific work on any infectious agent or toxin that enhances its pathogenicity or transmissibility and carries the potential for significant societal harm. It expressly prohibits funding for projects that seek or achieve any of seven high-risk outcomes: making a pathogen more harmful, undermining existing immunity or vaccines, conferring resistance to medical countermeasures or detection, increasing stability or dissemination, altering host range, enhancing host population susceptibility, or generating eradicated agents.1 The definition now explicitly includes mirror organisms.2
Important exclusions preserve legitimate work: basic characterization studies, vaccine development that attenuates a pathogen, and research using pseudotype viruses are not considered DGoF. Additionally, projects where modifications could incidentally produce a high-risk outcome are not automatically banned, but they must undergo third-party or federal review before proceeding.
Rooted in the May 2025 executive order on biological research safety, a centerpiece of the Trump health policy second term, this government-wide policy requires all federal agencies, including the National Institutes of Health, the Department of Defense, and the U.S. Department of Agriculture, to enforce identical standards. For instance, the USDA's National Institute of Food and Agriculture adopted the same DGoF definition and prohibited outcomes, as outlined in the USDA NIFA guidance on dangerous gain of function research. The NIH had already suspended dozens of pathogen studies over gain-of-function concerns before the formal policy release.3 Another blanket prohibition: federal money cannot fund any life sciences research in countries of concern.4
Principal investigators must now self-identify: they must attest in writing whether proposed work qualifies as DGoF.5 Institutions must establish an internal review entity to evaluate potential DGoF projects.1 Any research flagged as potentially falling within the policy's scope faces additional third-party or federal review.5 This shifts significant oversight responsibility onto public sector research institutions immediately.
The policy includes a call for public comment, allowing administrators, scientists, and the public to weigh in on implementation details. Stakeholders can submit input via the process outlined on the HHS website. This comment period is a critical window for public administrators to shape how the broad policy language translates into daily grant management and compliance workflows.
Under the 2026 policy, federally funded research that could enhance the pandemic potential of pathogens is now prohibited.1 The government-wide public policy directive targets life sciences experiments that modify biological agents to increase transmissibility, virulence, or resistance to countermeasures. While public administrators must consult the official policy text for a precise list, the following categories typically fall under scrutiny:
Many peer nations maintain their own oversight mechanisms for high-risk life sciences research. Germany's Central Committee for Biological Safety (ZKBS) evaluates dual-use research proposals, while the United Kingdom's Health and Safety Executive (HSE) oversees work with dangerous pathogens through a tiered approval system. Professional associations such as the American Society for Microbiology (ASM) provide cross-national policy summaries that can help public administration professionals understand global norms. These frameworks vary in strictness, but the U.S. policy aligns with a growing international consensus that certain experiments require robust justification and safeguards.
Did you know? The 2026 U.S. government-wide policy prohibits all federal funding for dangerous gain-of-function research in countries of concern. Other major research nations, such as the United Kingdom and Germany, continue to allow such research under strict regulatory oversight, creating a patchwork of international biosafety standards.
Compliance with the new government-wide policy demands a fundamental restructuring of institutional research oversight, not merely an addendum to existing procedures. Institutions receiving federal funds for life sciences research must now implement a tightly coordinated system of protocol registration, risk assessment, and multi-layered committee review that extends well beyond traditional biosafety mechanisms.
The core compliance pathway begins with protocol registration using a biorisk screening form that captures the scope and safety measures of any research involving high-risk pathogens. This triggers a Lab Activity Risk Assessment that evaluates the entire workflow, from agent handling to waste disposal. Following the assessment, the protocol must undergo enhanced review by an expanded Institutional Biosafety Committee (IBC) or a newly constituted Institutional Biosafety and Security Committee (IBSC), as seen at Algonquin College.1 For dual-use research of concern, a designated Institutional Review Entity (IRE) performs an additional screening for potential biosecurity threats. Federal agency reporting is required at multiple stages: initial protocol approval, any amendments, and annual compliance summaries.
Robust documentation is non-negotiable. Institutions must maintain a central repository that includes risk assessments, committee review minutes, training records, incident reports, and correspondence with federal agencies. The University of Ottawa's Biosafety and Biosecurity Governance Framework, for example, incorporates 13 discrete governance elements, ranging from agent inventory logs to emergency response plans. A Biohazard Permit Application must be filed and approved by the Biological Safety Officer (BSO) before work commences, and it must include a Laboratory Risk Assessment (LRA) and up-to-date standard operating procedures (SOPs). Annual audits of documentation are expected, with spot checks by federal inspectors.
Existing IRB and IBC structures cannot simply absorb these new demands; they must evolve. The NSABB's Proposed Biosecurity Oversight Framework for the Future of Science calls for a more integrated model where biosafety and biosecurity reviews are jointly conducted and risk mitigation plans are shared between committees. This means IRBs must now consider research with potential dual-use implications that previously fell only under IBC purview, while IBCs must incorporate security threat assessments. Some commentators, including the Bush School's proposal for an Independent Bioresponsibility Authority, advocate for a committee that merges these functions entirely, reducing fragmentation.
Several institutions have pioneered compliance workflows that serve as practical models. Thompson Rivers University's Plan for Administrative Oversight outlines 10 required elements, including a clear chain of responsibility from researcher to BSO to institutional executive, and a biorisk screening form as the gateway for all protocol reviews. The University of Melbourne's Biorisk Management Program2 emphasizes a tiered review: low-risk protocols receive expedited review, while high-risk ones undergo full committee evaluation with external expert input. La Trobe University's LTIBC3 mandates immediate reporting of Risk Group 3 agents and an annual inventory of Risk Group 2 agents, ensuring real-time tracking. These models demonstrate that proactive institutional design can streamline compliance while enhancing safety.
The 2026 policy marks a significant shift in federal funding for life sciences research. Agencies like the National Institutes of Health (NIH), National Science Foundation (NSF), and Department of Defense (DOD) are already altering their funding mechanisms to align with the comprehensive ban on dangerous gain-of-function studies mandated by the Executive Order on Improving the Safety and Security of Biological Research. Proposals involving any such research are now prohibited from receiving federal support, and grants will not be awarded for work that could enhance the transmissibility or virulence of potential pandemic pathogens.
Federal agencies are embedding the new restrictions into grant application requirements. The Office of Management and Budget (OMB) has proposed rules requiring pre-issuance review for all discretionary awards and making peer review advisory only.2 Funding can be terminated at any time for any reason,3 giving agencies broad discretion to halt projects that raise biosecurity concerns. Additionally, foreign collaborations with China, Russia, and Iran are prohibited,2 and even publication costs and conference attendance now require pre-approval or are disallowed entirely.3
A key operational change is the requirement for institutions to establish a single independent third-party review body within 90 days to evaluate high-risk research, as outlined in the Federal Research Regulations Threat to American Science. Grant proposals that involve certain pathogens or experimental techniques will automatically trigger this review. Administrators must develop internal processes to flag these proposals early, ensuring they do not proceed into agency review pipelines without proper vetting. This represents a shift from the decentralized oversight of the past, where institutional biosafety committees often had variable standards.
The 2014 gain-of-function moratorium provides a cautionary precedent.4 That 27-month pause on certain influenza, MERS, and SARS research caused a subset of NIH grants to be delayed or paused, leading some institutions to shift their portfolios away from these areas. While the pause ultimately strengthened biosafety infrastructure and training, it also created funding uncertainty that cooled some legitimate research. Administrators should anticipate similar ripple effects now, as investigators may hesitate to propose studies that could be misclassified as high-risk, even if they fall outside the prohibited scope.4
To mitigate chilling effects, grant administrators can proactively educate faculty on the precise definitions and exemptions within the new policy. They should work with sponsored programs offices to develop clear checklists for grant proposals and coordinate with the new review bodies to build institutional expertise. Prioritizing "gold standard" science and robust biosafety protocols can help maintain funding flows for compliant research, while ensuring that the institution remains aligned with federal expectations.
When the 2014 gain-of-function moratorium halted 18 NIH-funded projects across 14 institutions, research administrators had just 90 days to respond, a dynamic examined in an analysis of the moratorium's aftermath.[[LINK:1]] That compressed timeline forced a rapid maturation of internal workflows that still informs today's compliance posture. The new government-wide policy for stopping high-risk life sciences research, released by HHS in July 2026, places research administrators once again at the center of institutional adaptation, a responsibility explored in a study on implementing the US government's gain-of-function research policy.
Effective implementation starts with a deliberate chain of coordination. After the 2014 pause, institutions that navigated the process smoothly had already built multi-layered review systems, as highlighted in a study of the implications for institutional oversight. They linked biosafety committees, institutional review boards, legal counsel, and federal program officers into a single operational thread. Centralized tracking tools, often simple shared databases or compliance dashboards, gave each stakeholder visibility into a project's status. A designated research integrity officer or biosecurity lead served as the single point of contact, reducing the back-and-forth that otherwise bogs down grant management.
The 2014 experience offers concrete lessons. Institutions that treated the moratorium as a temporary hurdle often struggled when exceptions were eventually granted, five for MERS and two for HPAI research.1 Those that reoriented their pre-award checks to permanently include a select agent involvement review, a practice adopted after the 2001 anthrax attacks, were better positioned to manage risk without slowing legitimate science. The HHS Payload, Pathogen, and Performance (PPP) Review Framework, established after the moratorium, gave administrators a risk-benefit criteria checklist that can be adapted for the new policy's scope.2
Research administrators must reconcile competing priorities. Scientists rightfully push for minimal friction, while funders and the public demand rigorous biosecurity. The solution lies in proportional oversight. Not every pathogen study warrants the same scrutiny. Institutions that have succeeded tier their reviews: gain-of-function research that enhances transmissibility in mammals triggers the most stringent checks, while lower-risk work moves through a lighter process. This aligns with the Select Agent Program's core requirements (registration, security plans, personnel reliability, and incident reporting) but scales the administrative burden to actual danger.
The administrator's role is fundamentally translational. They interpret federal policy for bench scientists who may never read the Federal Register. They translate institutional compliance realities for program officers at HHS and NIH. After the 2014 experience, the National Science Advisory Board for Biosecurity (NSABB) explicitly highlighted this bridging function, noting that well-supported administrators are the strongest predictor of institutional compliance. For public administration students and emerging professionals, this is where theory meets practice: the ability to build a workflow that protects both scientific inquiry and public health is a core competency of modern research governance.
Effective oversight of high-risk life sciences research requires research administrators who are not only familiar with the new federal policy but also equipped with specialized competencies. Building this expertise involves engaging with a combination of federal training resources, professional competency frameworks, and academic programming.
Federal agencies provide foundational guidance for those managing dual-use research. The NIH Office of Science Policy and HHS offer online courses and policy documents that clarify oversight responsibilities under the current policy. These resources typically cover risk assessment methodologies, biosafety levels, and the administrative requirements for reviewing and monitoring funded projects. While program-specific details are still being developed for the latest policy, administrators should monitor these agency websites for updated materials and training modules that align with federal administration best practices.
Professional societies offer structured frameworks that define the knowledge and skills needed for high-risk research administration. Organizations like NCURA (National Council of University Research Administrators) and RAIN (Research Administrators Interest Network) have developed competency models that address areas such as compliance, ethics, and grant management for sensitive research portfolios. These frameworks are invaluable for designing internal training programs and for individual career development planning, as they align with the practical demands of implementing federal restrictions.
Universities increasingly offer certificates and specializations in research ethics, biosafety, and dual-use research oversight. These programs, often found within schools of public health, public policy, or law, provide deeper theoretical grounding and case-study analysis. Course catalogs available on university websites are the best source for identifying relevant offerings, which may be completed as standalone credentials or as part of a public administration degree or a related field.
To understand current expectations, administrators should review job postings for research compliance roles and cross-reference them with occupational profiles from the Bureau of Labor Statistics (BLS.gov). While BLS does not publish a dedicated category for research administrators, related classifications in compliance and management often highlight public administration certifications such as Certified Research Administrator (CRA) as preferred or required. This market-driven view helps emerging professionals prioritize which competencies to develop.
The public comment period is not a bureaucratic afterthought; it is a strategic lever for shaping public policy-making in real-world institutional settings.
The HHS call for public comment reflects the executive branch's procedural commitment to transparency. By opening the rulemaking docket, the agency signals that input from regulated parties, including universities, research hospitals, and federal grantees, carries weight. For public administrators, this process demonstrates how executive actions can incorporate structured feedback, balancing top-down authority with bottom-up practicality.
Research administrators should approach the comment process with the same rigor applied to grant proposals. Practical steps include:
Comments from research administrators directly influence the final implementation guidance. Regulators often amend definitions, clarify oversight responsibilities, or add implementation flexibilities based on feedback that highlights operational blind spots. By detailing how the policy interacts with existing grant management software, IRB procedures, or biosafety committees, administrators help transform abstract prohibitions into workable rules. This engagement ensures that public service values of accountability, feasibility, and transparency are built into the policy from the ground up.
Federal science policy is increasingly shaped by executive branch directives that test the boundaries of administrative procedure and public accountability. For students pursuing an MPA or MPP, the Trump administration's 2026 high-risk research policy represents more than a headline: it is a live case study in how government-wide mandates navigate interagency coordination, ethical boundaries, and evidence-based rulemaking.
The HHS-led policy forced coordination among multiple agencies, from NIH to NSF, mirroring the inter-organizational dynamics studied in public management courses. Students can trace how the policy's reliance on risk assessment frameworks connects to evidence-based rulemaking, an issue that is prompting a rethinking MPP and MPA curricula: administrators must define "high-risk" using scientific and ethical benchmarks, not just political preferences. Ethics coursework on the precautionary principle comes alive when officials must balance pathogen research that could yield pandemic vaccines against the same research that might spark an accidental outbreak.
The policy crystallizes the perennial tension between scientific freedom and public safety. In MPP ethics seminars, students debate whether restrictions on gain-of-function research constitute prudent oversight or stifle legitimate inquiry. This case forces them to move from theory to application: how should agencies design oversight that is rigorous yet flexible, and who gets to decide where the line is drawn? The public comment period itself offers a lesson in stakeholder engagement and the administrative state's responsiveness.
Students who find this intersection compelling can prepare for public administration jobs in research compliance, federal grant management, or science policy advisory positions. Practical steps include taking elective courses in regulatory policy, science and technology studies, and federal budgeting. Internships with the HHS Office of the General Counsel, the Office of Science and Technology Policy, or university sponsored projects offices provide direct exposure to the implementation challenges highlighted by the 2026 policy. For emerging professionals, heeding MPA first year advice can help build fluency in both the science and the administrative procedure, a distinctive career asset.
